Replies to post #242957 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

$ELTP can do its own Oxycodone/Naltrexone NDA 505B2, however it requires Clinical Trial at least Phase1/2A.

Nasrat is looking for shortcut by doing a generic Troxyca by making a Tablet instead of Troxyca Capsule.

And this is more from a stockholders given me advice on using roxycodone like Pfizer did, so we can overcome Pfizer's three year exclusivity that doesn’t happen, this is unrealistic, exclusivity will be given for company that makes a specific dosage for them and a specific type. So if you made the capsules, somebody else can make a tablet and it will be 505(b) 2 and you will get your own exclusivity. But Pfizer is making a capsule of roxycodone with Naltrexone, we cannot make another capsule and say let's waive their exclusivity because we used roxycodone as a reference's to drug, it doesn't work that way.

The pharmacological approach however can be used and is being used for us to create Oxy products. That would be Pfizer's TROXYCA. Elite expect to develop a generic for TROXYCA as soon as Pfizer launches the product.

Elite expect to develop a generic for TROXYCA as soon as Pfizer launches the product.